From GlobeNewswire:

OPKO Health, Inc. has announced a private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029. The Notes will bear interest at a rate of 3.75% per annum, payable semiannually. The initial conversion rate of the Notes is 869.5652 shares of common stock per $1,000 principal amount, equivalent to an initial conversion price of approximately $1.15 per share. The Company estimates that the net proceeds from the offering will be approximately $192.5 million and the sale is expected to close on January 9, 2024. The offering is not conditioned upon the closing of a concurrent private placement of Affiliate Notes. Any remaining net proceeds will be used for general corporate purposes. The Notes and any shares of common stock issuable upon conversion of the Notes have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption. OPKO Health is a multinational biopharmaceutical and diagnostics company. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute an offer to purchase, or notice of redemption, with respect to the 2025 Convertible Senior Notes, and the Company reserves the right to elect not to proceed with the note repurchases described above. This press release does not constitute an offer to repurchase shares of common stock, and the Company reserves the right to elect not to proceed with the common stock repurchases described above. To learn more, visit www.opko.com.



Read more: OPKO Health Announces Pricing of Private Offering of $200